| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NPPB |
| Uniprot No | P16860 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 37-71aa |
| 氨基酸序列 | DLETSGLQEQRNHLQGKLSELQVEQTSLEPLQESP |
| 预测分子量 | 31.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NPPB(B型钠尿肽前体)重组蛋白的3篇参考文献及摘要概括：
1. **"Expression and purification of recombinant human brain natriuretic peptide (BNP) in Escherichia coli"**
- **作者**: Chen, Q. et al.
- **摘要**: 研究描述了一种通过大肠杆菌表达系统高效生产重组人BNP(rhBNP)的方法，优化了蛋白纯化流程，并验证其生物活性(如利尿和血管舒张功能)，为临床应用提供基础。
2. **"Characterization of recombinant human proBNP and its derived peptides"**
- **作者**: Schellenberger, U. et al.
- **摘要**: 通过哺乳动物细胞表达重组人proBNP(NPPB前体蛋白)，分析其蛋白水解加工过程及产生的BNP片段活性，揭示了重组proBNP在心力衰竭生物标志物开发中的潜力。
3. **"Recombinant B-type natriuretic peptide (Nesiritide) for acute heart failure: a systematic review"**
- **作者**: O'Connor, C.M. et al.
- **摘要**: 综述重组BNP(奈西立肽)在急性心力衰竭治疗中的临床效果和安全性，总结其血流动力学改善作用及剂量相关副作用，强调需进一步研究优化治疗方案。
---
**备注**：NPPB基因编码的proBNP蛋白经酶切生成BNP，重组BNP常用于心血管疾病研究及治疗。以上文献涵盖重组蛋白表达、功能分析及临床应用方向。如需具体年份或期刊信息，可进一步补充关键词检索。
**Background of NPPB Recombinant Protein**
NPPB (Natriuretic Peptide Precursor B), also known as brain natriuretic peptide (BNP), is a cardiac hormone encoded by the *NPPB* gene. It belongs to the natriuretic peptide family, which includes atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). NPPB is synthesized as a preprohormone and processed into the active BNP, a 32-amino-acid peptide. It is primarily secreted by cardiac ventricular myocytes in response to myocardial stretch or volume overload, playing a critical role in regulating blood pressure, electrolyte balance, and cardiovascular homeostasis.
Recombinant NPPB protein is produced using biotechnological methods, such as *E. coli* or mammalian expression systems, to ensure high purity and bioactivity. This engineered protein retains the functional properties of native BNP, including binding to the natriuretic peptide receptor-A (NPR-A) to activate guanylyl cyclase signaling. This pathway promotes vasodilation, natriuresis, and diuresis, counteracting the renin-angiotensin-aldosterone system.
In research, recombinant NPPB is widely used to study cardiovascular diseases (e.g., heart failure, hypertension), renal function, and fluid homeostasis. It serves as a biomarker for diagnosing and prognosticating heart failure, as elevated BNP levels correlate with disease severity. Additionally, recombinant NPPB aids in drug development, acting as a reference standard for therapeutic peptides or NPR-A-targeted agents. Its applications extend to *in vitro* and *in vivo* models to dissect molecular mechanisms of natriuretic peptide signaling and evaluate potential therapies.
Overall, recombinant NPPB is a vital tool for understanding cardiovascular pathophysiology and advancing translational research in cardiorenal medicine.
×
